13results about How to "Improve lung function" patented technology

The invention relates to the technical field of biological medicine, in particular to a composite drug-loaded nano preparation and a preparation method thereof. The composite drug-loaded nano-preparation comprises a drug-loaded nano-liposome, and a biological enzyme and a myofibroblast targeting ligand which are loaded on the surface of the drug-loaded nano-liposome, the drug-loaded nano-liposome is a nano-liposome in which an anti-fibrosis drug is encapsulated; the mass ratio of the drug-loaded nano-liposome to the biological enzyme to the myofibroblast targeting ligand is (6-15): (0.5-4): (0-3). According to the invention, a composite drug-loaded nano preparation for pulmonary drug delivery in an aerosol inhalation manner is constructed, and the myofibroblast targeting ligand and the biological enzyme are jointly modified on the surface of the drug-loaded nano liposome; and the composite nano preparation (CLG-CS-FAP-NIN) which has myofibroblast targeting and can degrade excessive collagen in an extracellular matrix is prepared and is used for treating the pulmonary fibrosis.

The invention provides an eucheuma compound for improving lung function and a preparation method thereof. The eucheuma compound is prepared from the following raw materials in parts by weight: 25 to 35 parts of eucheuma extract, 13 to 17 parts of oyster peptide, 8 to 12 parts of fish collagen peptide, 4 to 6 parts of rhizoma polygonati, 3 to 5 parts of herba cistanche, 2 to 4 parts of semen euryales and 1 to 2 parts of longan. Secondly, the eucheuma extract rich in eucheuma polysaccharide, eucheuma polypeptide and the like is prepared through the technology. The components in the formula of the eucheuma compound have a synergistic effect, and the prepared eucheuma compound can effectively control the lung coefficient and increase of the hydroxyproline content in lung tissue and improve inflammatory infiltration and fibrohyperplasia of the lung. In addition, the compound also inhibits oxidative stress reaction and further inhibits pulmonary fibrosis; the lung lesion is effectively inhibited, the lung function is improved, and the lung health is promoted.

The invention discloses a stem cell preparation for treating pulmonary fibrosis. The stem cell preparation is mesenchymal stem cell surface modified nanoparticles. The nanoparticles are ROS (reactive oxygen species) response type lipid polymer hybrid nanoparticles loaded with an anti-fibrosis drug. According to the invention, a hydrophobic drug and a hydrophilic anti-fibrosis drug can be simultaneously loaded through the reductive hybrid nanoparticles, and can be delivered to the lung by utilizing the inflammation targeting capability of stem cells. The polymer in the nanoparticles reacts with active oxygen in the microenvironment to promote drug release, and then the effect of protecting stem cells is achieved. The released medicine can induce dedifferentiation of myofibroblasts and inhibit apoptosis of vascular endothelial cells and endothelial mesenchymal transformation, and the mesenchymal stem cells release growth factors at the same time to promote angiogenesis, reconstruct capillary structures deleted in fibrosis areas, promote lung tissue regeneration and recover lung functions to achieve the effect of treating pulmonary fibrosis.

The application belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine compound for treating pulmonary fibrosis of diabetes and application thereof. The traditional Chinese medicine compound comprises 70-90 parts of Huangqi, 20-40 parts of Danshen, 10-30 parts of Chuanxiong, 20-40 parts of Beishashen and 40-60 parts of Shanyao. The application also discloses application of the traditional Chinese medicine compound in preparation of a medicine for treating pulmonary fibrosis of diabetes of the type of deficiency of both qi and yin and blood stasis. The traditional Chinese medicine compound has reasonable formula, and uses the traditional Chinese medicine theory scientifically. The raw materials are matched according to the principle of monarch, minister, assistant and guide, and the traditional Chinese medicines are synergistically used, so that the traditional Chinese medicine compound can not only supplement deficiency of both qi and yin of diabetes, but also dredge stasis of collaterals of long-term disease, and achieve good clinical test effect by considering both the symptoms and the root cause.

The invention provides an IAA (Indoleacetic Acid)-PAMAM (Polyamidoamine) G4 nano-composite. The nano-composite is prepared by combining 3-indoleacetic acid and a fourth-generation polyamide-amine type dendrimer together in an ultrasonic manner. The invention further discloses a preparation method of the IAA-PAMAM G4 nano-composite and application of the IAA-PAMAM G4 nano-composite in prevention or treatment of chronic obstructive pulmonary diseases. According to the IAA-PAMAM G4 nano compound disclosed by the invention, the water solubility and the stability of 3-indoleacetic acid are effectively improved, and the anti-inflammatory effect of the 3-indoleacetic acid is enhanced. The IAA-PAMAM G4 nano-composite disclosed by the invention can directly act on the lung in an aerosol inhalation manner, so that the inflammatory response is relieved, and the lung function is improved. In a mouse chronic obstructive pulmonary disease model, a remarkable effect is shown, the pathological change of chronic obstructive pulmonary diseases is relieved, and the lung function is remarkably improved. In addition, the IAA-PAMAM G4 nano-composite also shows an inhibition effect on expression of inflammatory factors in an in-vitro cell experiment, and the cell inflammation level is reduced.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition capable of eliminating pulmonary nodules and a preparation method thereof. The traditional Chinese medicine comprises astragalus membranaceus, codonopsis pilosula, poria cocos, roasted rhizoma atractylodis macrocephalae, honey-fried licorice root and the like, treats both symptoms and root causes, breaks through the limitation of traditional pulmonary nodule treatment, and can accelerate blood flow and condition physique while treating pulmonary nodule; the traditional operation method is broken through by eliminating phlegm, removing dampness, promoting blood circulation to remove blood stasis and softening hardness to dissipate stagnation, and pulmonary nodules caused by imbalance of viscera and imbalance of yin and yang can be adjusted; according to the traditional Chinese medicine composition, a plurality of medicines are combined and comprehensively attacked, the lung function is improved, yin-yang balance is corrected, and nodules are eliminated.

The application belongs to the technical field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition for treating Klebsiella pneumoniae pneumonia and a preparation method thereof. The traditional Chinese medicine composition is prepared from eight raw medicinal materials of Zhejiang fritillary bulb, white mulberry bark, Chinese plume-pod seed, dandelion, platycodon root, lily, apricot kernel and poria cocos. The composition has the effects of promoting lung and clearing heat, relieving cough and reducing sputum, and strengthening body resistance and eliminating pathogenic factors. Pharmacodynamic experiments show that the composition has a significant therapeutic effect on Klebsiella pneumoniae pneumonia.

The pharmaceutical composition according to the present invention can be usefully used for the prevention or treatment of systemic fibrosis.

The invention provides a traditional Chinese medicine composition and traditional Chinese medicine decoction for preventing and / or treating interstitial lung diseases as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from 25-35 parts of radix astragali, 15-25 parts of radix codonopsis, 10-15 parts of rhizoma atractylodis macrocephalae, 10-20 parts of poria cocos, 10-15 parts of semen armeniacae amarae, 10-15 parts of radix platycodonis, 10-20 parts of radix salviae miltiorrhizae, 10-20 parts of rhizoma chuanxiong, 10-15 parts of radix angelicae sinensis, 4-10 parts of fructus schizandrae and 5-12 parts of radix glycyrrhizae, the radix astragali, the radix codonopsis, the rhizoma atractylodis macrocephalae and the poria cocos are combined to serve as monarch drugs to achieve the effect of tonifying qi, and the radix salviae miltiorrhizae, the radix angelicae sinensis and the rhizoma chuanxiong are combined to serve as ministerial drugs to jointly achieve the effect of promoting blood circulation to remove blood stasis. The radix platycodonis, the semen armeniacae amarae and the fructus schizandrae are combined to serve as adjuvant drugs and jointly achieve the effects of relieving cough and asthma, and the liquorice serves as conductant drugs, has the effect of regulating drug properties and jointly achieves the effects of tonifying qi (lung and spleen), promoting blood circulation to remove blood stasis and relieving cough and asthma, so that the interstitial lung diseases are prevented and / or treated.

This invention provides a DNA nanowire capable of breaching the mucus barrier in COPD, its preparation method, and its application in the preparation of drugs for preventing and treating lung infections, belonging to the field of nanomedicine technology. The DNA nanowire of this invention utilizes a strongly positively charged antibiotic AMK and a divalent cation Mg²⁺. + The synergistic effect of streptavidin and biotin forms a stable DX tile structure. Subsequently, utilizing the high affinity between streptavidin and biotin, the biotin-modified Biotin-NAC is precisely anchored to the 5' end of the M chain, achieving a combined loading of mucolysis and subsequent immunomodulatory functions. Through a strain-induced azido-alkyne cycloaddition reaction, the DBCO-modified L chain is covalently linked to the azido-modified neutrophil chemotactic peptide Ac-PGP to form a stable triazole structure, endowing the platform with chemotactic ability for CXCR2-overexpressing neutrophils. The DNA nanowires of this invention can effectively prevent and treat lung infections in COPD patients.

This invention provides an application of 1-O-acetyl-Inula japonica lactone, which is used to prepare drugs for improving acute lung injury. This invention utilizes network pharmacology, molecular docking, and molecular dynamics simulations to analyze that the Keap1-Nrf2 signaling pathway is a key potential target for Inula japonica in treating acute lung injury. The characteristic component of Inula japonica, 1-O-acetyl-Inula japonica lactone, exerts antioxidant and anti-inflammatory effects by targeting Keap1 and activating the Nrf2 signaling pathway. This invention provides important evidence for the application and new drug development of 1-O-acetyl-Inula japonica lactone.

The present disclosure provides a novel strain of Lactobacillus plantarum GCWB1001, Pediococcus acidilactici GCWB1085, or Lactobacillus rhamnosus GCWB1156, wherein the Lactobacillus plantarum GCWB1001, the Pediococcus acidilactici GCWB1085, the Pediococcus acidilactici GCWB1085, the Lactobacillus rhamnosus GCWB1156, the Lactobacillus plantarum GCWB1001, the Pediococcus acidilactici GCWB1085, the Lactobacillus rhamnosus GCWB1156 having a preservation number KCCM12698P, and the Furthermore, a pharmaceutical composition, a health-care functional food composition and a probiotic are provided, each comprising any one of the novel strains and having an effect of treating or alleviating inflammatory diseases or respiratory diseases.

The invention discloses application of a human umbilical cord mesenchymal stem cell exosome in promotion of lung development and a verification method, and relates to the technical field of biological medicine.The key point of the technical scheme is that the human umbilical cord mesenchymal stem cell exosome remarkably promotes the pulmonary alveolation process and improves the lung structure and function through rich Wnt5a, so that the lung development is promoted, and the lung development is promoted. The morbidity of bronchial lung dysplasia of premature infants is reduced; by activating a Wnt5a / ROCK1 pathway, the exosome enhances differentiation and self-repairing capabilities of alveolar epithelial cells, accelerates synthesis of alveolar surfactants, and improves lung functions and stability; as a biological treatment means, the exosome is high in safety and low in immunogenicity, side effects and complications of drugs are reduced, and clinical transformation potential for treating lung dysplasia of premature infants is shown.